Ivonescimab Plus Chemotherapy Fails Cost-Effectiveness Test in Advanced Squamous Lung Cancer
A cost-effectiveness model based on the HARMONi-6 trial finds that ivonescimab plus chemotherapy is unlikely to be cost-effective for advanced ...
A cost-effectiveness model based on the HARMONi-6 trial finds that ivonescimab plus chemotherapy is unlikely to be cost-effective for advanced ...
A qualitative study of 14 Brazilian patients found that before starting treatment for lung or head and neck cancer, most ...
A systematic review and meta-analysis of six studies covering 2,479 patients found that antibody-drug conjugates significantly improved progression-free and overall ...
Genome sequencing of normal oesophageal tissue shows that chemotherapy and chemoradiotherapy select for distinct mutant clones in healthy cells, including ...
A Bayesian reanalysis of the RELEVANCE trial found extremely low probabilities that rituximab plus lenalidomide was inferior to rituximab plus ...
A cross-sectional mixed-methods study of 213 women with breast cancer in Türkiye found reported intimate partner violence in every participant ...
A meta-analysis of six randomized trials found that adding PD-1/PD-L1 inhibitors to chemotherapy was associated with longer progression-free and overall ...
A retrospective cohort of 163 patients treated at one Rwandan cancer center reported estimated median overall survival of 3.68 years ...
A simulation study couples a chaotic three-dimensional tumor growth model with an advanced filtering technique to estimate tumor, host, and ...
Epstein-Barr virus-associated gastric cancer (EBVaGC) has long been regarded as the most immunologically favorable form of a disease that remains ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine